Autologous vs Allogeneic: What Therapeutic Developers and Manufacturers Really Need to Know

Georgi Makin
16 March 2023
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Gene Therapy
GMP
Logistics
Patient Access & Engagement
Regulatory & Standards
Scaling Up
Strategy
Supply Chain
Rupa Pike, Senior Director of Technical Affairs, Advanced Therapies, Thermo Fisher Scientific, joined us live at Advanced Therapies Week 2023 to discuss and shed some light on the current autologous vs allogeneic cell therapy landscape.
Discussing arguably one of the biggest debates in cell and gene therapy right now, autologous vs allogeneic, Rupa first takes a broad look at the market trends we are seeing in CGT development and manufacturing, before zooming in on the CDMO preparations, as well as supply chain and logistical considerations required for each method.
Rupa then goes on to consider the importance of mitigating manufacture risks in the unique regulatory environment that advanced therapies are developed and commercialized in, noting the benefits of collaboration to novel therapy delivery.
This interview has been produced in partnership with Thermo Fisher Scientific and was recorded at Advanced Therapies Week 2023.
![]() |
![]() |
More like this
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14 March 2023
Early Adoption and Partnerships – The Secret to Commercialization Success?
This Briefing from Advanced Therapies Week 2023 focusses on how partnerships within the industry can advance research from the clinic to manufacturing scale, to keep pace with the evolving field.
2 March 2023